DEFA14A: Beneficient Secures $1.91 Million Primary Capital Through Preferred Stock Issuance to Expand Alternative Asset Portfolio

Beneficient has closed a $1.91 million primary capital transaction by issuing Series B-8 Resettable Convertible Preferred Stock in exchange for a limited partner interest in an investment fund, aiming to expand its alternative asset portfolio and liquidity solutions.

Summary

• Beneficient closed a primary capital transaction on June 17, 2025, for which an agreement was entered on May 22, 2025.
• The transaction involved acquiring a limited partner interest in an investment fund with a net asset value of $1,910,370.
• In exchange, the customer received 191,037 shares of Beneficient's Series B-8 Resettable Convertible Preferred Stock, valued at $10.00 per share, totaling $1,910,370.
• The Series B-8 Preferred Stock is convertible into Class A Common Stock at an initial price of $0.3397 per share, subject to monthly resets based on the five-day trailing volume-weighted average price, with a floor of $0.2548 and a cap of $0.3397.
• A maximum of 7,497,528 shares of Class A Common Stock may be issued upon conversion.
• The issuance was unregistered, relying on Section 4(a)(2) and Regulation D of the Securities Act.
• This marks Beneficient's third GP Primary transaction of the fiscal year and fourth since launching the program in late 2024.
• The transaction is expected to increase the collateral for Beneficient's ExAlt loan portfolio by approximately $1.91 million in alternative asset interests.
• Beneficient also entered into a Preferred Liquidity Provider Program Agreement with the fund, enabling the company to facilitate ongoing liquidity solutions for the fund and its limited partners.

Sentiment

Score: 7

Explanation: The transaction represents a successful execution of the company's stated strategy to expand its primary capital solutions program, bringing in new assets and increasing collateral. While there are complexities and limitations related to the preferred stock conversion, the overall tone and strategic alignment are positive, indicating progress in their business model.

Positives

• Secured $1.91 million in primary capital, expanding the company's alternative asset portfolio.
• Increased collateral for the ExAlt loan portfolio by approximately $1.91 million.
• Represents the third GP Primary transaction of the fiscal year and fourth since the program's late 2024 launch, indicating momentum in this strategic area.
• Established a Preferred Liquidity Provider Program Agreement, potentially creating new revenue streams and strengthening relationships.
• The transaction aligns with Beneficient's strategic vision to democratize the alternative asset market and provide liquidity solutions.

Negatives

• The Series B-8 Preferred Stock ranks junior to several existing series of preferred stock (Series A, B-1 through B-7) and all existing and future indebtedness, which could impact recovery in a liquidation scenario.
• The Series B-8 Preferred Stock has no voting rights, limiting the influence of these new preferred stockholders.
• The conversion of preferred stock into Class A Common Stock is subject to a 4.99% beneficial ownership limitation and a Nasdaq Exchange Cap, which may delay or limit full conversion without stockholder approval.
• The Series B-8 Preferred Stock is not redeemable by the company, meaning the company cannot force conversion or repurchase.
• The Series B-8 Preferred Stock cannot be sold, assigned, or transferred without the company's written consent, limiting liquidity for the holder.

Risks

• The issuance of Class A Common Stock upon conversion of the Series B-8 Preferred Stock is subject to stockholder approval to exceed the Nasdaq Exchange Cap, and failure to obtain this approval could delay or limit conversions.
• The conversion price is subject to monthly resets based on the Class A Common Stock's volume-weighted average price, which introduces variability and potential dilution if the stock price declines.
• The company's ability to file all required annual and quarterly reports (10-K and 10-Q) is a condition for mandatory conversion on the fifth anniversary, and failure to do so could delay conversion.
• The forward-looking statements regarding the transaction and stock issuance involve risks and uncertainties, as detailed in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Beneficient plans to continue pursuing additional primary capital opportunities that align with its strategic vision and growth objectives, aiming to satisfy a significant market demand for primary commitments to meet fundraising needs, estimated at up to $330 billion.

Management Comments

• "We are excited to continue recent momentum by completing another GP primary capital transaction, our second transaction with a fund managed by the Fund Manager."
• "We will continue to pursue additional opportunities that align with our strategic vision and growth objectives."

Industry Context

This transaction highlights Beneficient's continued expansion in the alternative asset market, specifically targeting General Partners seeking primary capital solutions. The company's focus on democratizing access to alternative asset liquidity for mid-to-high net worth individuals and small-to-midsized institutions positions it in a niche but growing segment. The stated market demand of up to $330 billion for primary commitments underscores the significant opportunity Beneficient is addressing with its GP Primary Commitment Program, differentiating itself by providing anchor commitments and value-added services.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if Series B-8 Preferred Stock converts into Class A Common Stock, especially if the conversion price resets lower. Requires stockholder approval for conversions exceeding the Nasdaq Exchange Cap.
• Preferred Stock Holders (Series B-8): Receive preferred stock convertible into common stock, with a reset mechanism for conversion price. Limited voting rights and transfer restrictions. Junior ranking to other preferred series and all indebtedness.
• Customers (Limited Partner): Received preferred stock in exchange for their limited partner interest, providing an exit opportunity.
• Creditors: Series B-8 Preferred Stock ranks junior to all existing and future indebtedness, providing a layer of protection for creditors.

Next Steps

• File a preliminary proxy statement and a definitive proxy statement with the SEC to seek stockholder approval for the issuance of Class A Common Stock upon conversion of the Series B-8 Preferred Stock in excess of the Nasdaq Exchange Cap.
• Continue to pursue additional primary capital opportunities that align with strategic vision and growth objectives.

Key Dates

Recommendation

Keywords

Beneficient, BENF, SEC Filing, 8-K, DEFA14A, Preferred Stock, Convertible Preferred Stock, Series B-8 Preferred Stock, Primary Capital Transaction, Alternative Assets, Investment Fund, Mendoza Ventures, GP Primary Commitment Program, Liquidity Solutions, Corporate Finance, Equity Financing, Nasdaq, SEC, Financial Services, Asset Management